Nezam El-Tayebat 事实核查对“نظام الطيبات”饮食体系的科学评估
选择国家
选择语言: 简体中文

错误 已被科学证据否定 证据确定性: 高 初步 C-DIAB-01

高血糖不是一种疾病，而是身体“拯救”您的保护性反应；根本不存在糖尿病这回事（“喝糖吧”）；糖的摄入量没有上限；糖化血红蛋白（HbA1c）是个谎言。

安全提示: 请不要忽视持续偏高的血糖或糖化血红蛋白（HbA1c）。血糖持续偏高（例如空腹血糖高于250-300 mg/dL）、体重下降、口渴和尿频，需要及时就医评估。
简而言之: 该说法错误。随机对照试验和大型队列研究表明，长期高血糖会造成眼、肾、神经和心脏损害并导致早死；糖化血红蛋白（HbA1c）能可靠地反映平均血糖水平；卫生机构也为糖的摄入设定了上限。只有在急性疾病期间血糖短暂升高，才可能是一种适应性反应。
结论: 长期高血糖是有害的；否认糖尿病的存在是错误且危险的。
  1. 原始表述
  2. 科学评估
  3. 科学证据详解
  4. 通俗解释
  5. 与该说法相关的研究
  6. 地区背景
  7. 在我的国家适用什么？
  8. 参考文献

原始表述

ان السكر عالي فسبب مشاكلك ده هو عالي عشان يلحقك اصلا

按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。

译文

高血糖不是一种疾病，而是身体“拯救”您的保护性反应；根本不存在糖尿病这回事（“喝糖吧”）；糖的摄入量没有上限；糖化血红蛋白（HbA1c）是个谎言。

出处

来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
Dr Diaa Al Awady د ضياء العوضي is live! الكورتيزون حياتك (打开来源)
发布日期
2025年10月17日
时间戳
1:57:07 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
所声称的机制

Stress hormones raise glucose to supply the brain; complications come from gut problems, not glucose.

所声称的健康影响

Denial of hyperglycaemia as harmful

涉及人群

People with diabetes

Elawady 设定的地域限制

none found

来源版本存在差异

来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
Dr.D Clinics - Diaa Al Awady is live! (打开来源)
发布日期
2025年1月12日
时间戳
无（转录文本不含时间信息）
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
Dr Diaa Al Awady د ضياء العوضي is live! مفيش حاجه سعرات مفيش حاجه اسمها نشويات (打开来源)
发布日期
2025年8月7日
时间戳
无（转录文本不含时间信息）
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
أكذوبة السكر التراكمي (打开来源)
发布日期
2025年4月17日
时间戳
无（转录文本不含时间信息）
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.

السكر العالي السكر العالي السكر العالي السكر العالي ماله مفيد لدماغك ومخك وشبكيتك الفيديو بتاع ياسر ومراته كان سكره 700

High sugar, high sugar - what is wrong with it? It is beneficial for your brain, your mind and your retina. The video of Yasser and his wife: his sugar was 700.

来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا ذكري يوم ميلادي 😂😂❤️❤️❤️ (打开来源)
发布日期
2026年3月26日
时间戳
1:08:26 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain speech-recognition errors; speaker turns are not marked, the excerpt was judged to be Elawady's own speech from context.

يعني انت عايز تقول ان السكر طول ما هو عالي بيحافظ عليك اه ومجرد ما توقعه مجرد ما توقع السكر عن المستوى اللي وصل له بقى ال 500 ولا ال 700 اللي انت شفتهم تنزلهم 200اني انت تطفي بقى كل حاجه

'So you mean that as long as the sugar is high it protects you?' 'Yes. As soon as you drop the sugar from the level it reached - the 500 or 700 you saw - down to 200, you switch everything off.'

来源状态
视频转录文本（本人原话）
归属
Elawady (machine transcript)
视频
Live highlight (打开来源)
发布日期
2026年4月6日
时间戳
无（转录文本不含时间信息）
归属的不确定性
Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain speech-recognition errors; speaker turns are not marked, the excerpt was judged to be Elawady's own speech from context. Question-and-answer passage in a short highlight clip: the question may be spoken by an interviewer; the affirmative answer and continuation are attributed to Elawady.

科学评估

错误 – 该说法与可靠证据相矛盾。

证据确定性: 高 – 进一步研究极不可能改变该评估。

1. 说法是什么？

High sugar is protective; diabetes does not exist; HbA1c is a lie; unlimited sugar is fine.

2. 哪些内容可证实是正确的？

Acute stress (illness, surgery, exercise) raises glucose through cortisol, adrenaline and glucagon; transient stress hyperglycaemia is a real phenomenon and some critical-care researchers consider it adaptive (I-DIAB-107); tight glucose control in critically ill patients increased mortality (A-INS-02). HbA1c can be misleading in anaemia, haemoglobin disorders or G6PD deficiency (I-DIAB-108). Overly aggressive glucose lowering can harm (C-INS-04).

3. 哪些内容是错误或夸大的？

Each 1% reduction in HbA1c was associated with 21% fewer diabetes-related deaths, 14% fewer myocardial infarctions and 37% fewer microvascular complications, with no threshold (I-INS-04). Intensive therapy reduced retinopathy by 76% in type 1 diabetes (I-INS-03) and microvascular endpoints by 25% in type 2 (A-INS-16). HbA1c is a validated measure of average glucose. 'Drink sugar' and 'no upper limit' contradict evidence on sugar-sweetened beverages and diabetes risk (topic of another rule).

4. 哪些内容仍不明确？

It is unclear how literally followers understand slogans such as 'there is no such thing as diabetes'; no outcome data among followers were found. The adaptive role of short-term stress hyperglycaemia in acute illness is still studied, but this does not apply to chronic hyperglycaemia.

5. 哪些研究支持该说法？

None for the general claim.

6. 哪些研究与该说法相矛盾？

I-INS-03, I-INS-04, A-INS-16, I-INS-02, I-INS-103 (mortality rises with HbA1c in T1D), I-INS-104, I-DIAB-106 (HbA1c tracks average glucose, R2 0.84), I-SUG-03 and A-SOD-01 (sugars and sugar-sweetened beverages).

7. 对德国和欧洲而言情况如何？

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

8. 关于埃及的已知情况是什么？

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. 合理的实际结论是什么？

长期高血糖会损害眼睛、肾脏、神经和血管。避免把控制目标定得过低是合理的；但忽视高血糖则不然。

评估详情

证据确定性的依据

Prospective data (UKPDS 35) show a continuous relationship between HbA1c and complications without threshold; RCTs (DCCT, UKPDS) show that lowering glucose reduces retinopathy, nephropathy and neuropathy. Stress hyperglycaemia exists (kernel), but chronic hyperglycaemia causes organ damage.

来源质量

Own words, several machine transcripts.

地区可推广性

Universal.

说法的地域范围
普遍性（生物学/医学）
最近审核
2026年10月26日 初步

科学证据详解

已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。

研究问题: In people with diabetes, is chronically raised blood glucose (HbA1c) harmless or protective, is HbA1c an invalid measure, and is there no upper limit for sugar intake?

研究问题详解 (PECO)
人群
People with type 1 or type 2 diabetes; general population for sugar intake
干预或暴露
Chronic hyperglycaemia (higher HbA1c); high sugar intake
对照
Lower HbA1c; lower sugar intake
地域范围
universal biology
结局指标
  • Microvascular and macrovascular complications
  • Mortality
  • Validity of HbA1c as average glucose
  • Type 2 diabetes incidence (sugar-sweetened beverages)

研究结果按作者报告呈现。我们的评估见下文。

哪些证据支持该说法？

  • Is high blood sugar during severe illness protective?

    Marik PE, Bellomo R. Crit Care 2013 · PMID 23470218 · DOI 10.1186/cc12514 叙述性综述已核查摘要新增

    Critical-care review arguing that short-term stress hyperglycaemia in acute illness is an adaptive survival response.

    实际结果
    No quantitative result; argues tight ICU glucose control did not improve outcomes.
    方法学质量
    low (opinion/narrative review)
    相关性
    indirect: acute critical illness, not chronic diabetes
    局限
    Does not concern chronic hyperglycaemia; opinion-based.

    原始文献

  • Very tight blood sugar control in intensive care

    NICE-SUGAR Study Investigators; Finfer S et al.. N Engl J Med 2009 · PMID 19318384 · DOI 10.1056/NEJMoa0810625 随机对照试验已核查摘要

    NICE-SUGAR: tight glucose control in critically ill patients increased mortality.

    实际结果
    Death 27.5% vs 24.9%, OR 1.14 (1.02-1.28).
    方法学质量
    high (large RCT)
    相关性
    indirect: supports that aggressive lowering in acute illness harms, not that high glucose is protective in diabetes
    局限
    ICU setting only.

    原始文献

  • When HbA1c can be misleading

    Samajdar SS et al.. Lancet Reg Health Southeast Asia 2026 · PMID 41743216 · DOI 10.1016/j.lansea.2026.100724 叙述性综述已核查摘要新增

    Review of HbA1c pitfalls (anaemia, haemoglobinopathies, G6PD deficiency, assay problems).

    实际结果
    Narrative; recommends adding glucose measures.
    方法学质量
    low (narrative review)
    相关性
    indirect: shows HbA1c can mislead in specific conditions
    局限
    Does not show HbA1c is invalid in general.

    原始文献

哪些证据不支持该说法？

总体证据说明了什么？

基于上述研究的编辑评估——其本身并非研究结果。

哪种观点有更好的证据支持？

Chronic hyperglycaemia causes organ damage and death; HbA1c is a validated measure of average glucose; sugar intake has upper limits recommended by WHO/EFSA.

为什么有些研究权重更大

RCTs (DCCT, UKPDS) and large cohorts with dose-response outweigh an opinion paper on acute stress hyperglycaemia and a review of HbA1c pitfalls.

因果关系是否已确立？ 是，已确立 Randomised lowering of glucose reduces complications (DCCT, UKPDS) with dose-response in cohorts.

仍存在的不确定性

Optimal glucose in acute critical illness; HbA1c accuracy in anaemia/haemoglobinopathies.

合理的结论

The claim is false; only the acute-stress kernel and HbA1c caveats are correct.

为什么研究结果看起来互相矛盾？

Apparent conflict between 'stress hyperglycaemia is adaptive' (I-DIAB-107, A-INS-02) and 'hyperglycaemia is harmful' (I-INS-03/04) reflects different questions: hours to days of acute illness versus months to years of diabetes. HbA1c limitations (I-DIAB-108) concern specific blood disorders, not the general validity shown by ADAG (I-DIAB-106).

这是否取决于国家？
一般生物学效应
Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
饮食习惯
High intake of sugar-sweetened beverages occurs in Egypt and Europe; WHO/EFSA limits apply to both.
食品原产地
Not relevant.
污染物
Not relevant.
本国生产条件
Not relevant.
法律规则
Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
实际监测数据
HbA1c can be distorted by anaemia and haemoglobin disorders, which are common in Egypt; this calls for added glucose testing, not abandonment of measurement.

足以改变结论的地区差异没有可靠数据支持。

统计复核
  • Convert HbA1c to estimated average glucose with the published regression – HbA1c 7% = 154 mg/dL, 9% = 212 mg/dL, 12% = 298 mg/dL; R2 0.84 indicates strong but imperfect individual agreement 已重新计算
  • Crude mortality and CI symmetry – Crude death 8.0% vs 2.9% (crude ratio 2.79); CIs log-symmetric 已重新计算
总体证据的确定性（GRADE，简化版）
主要结局
Microvascular complications and mortality with chronic hyperglycaemia
起始等级
高（随机试验）
升级理由
  • dose-response (UKPDS 35, Lind 2014)
结果
高

由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。

已核查的临床指南和官方声明
  • ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · 原始文献
    People at risk for DKA should have ketone testing tools and sick-day advice; people on intensive insulin therapy should not stop or hold basal insulin even if not eating; caution with near-normal A1C goals in long-standing T2D using hypoglycaemia-prone drugs (ACCORD).
  • WHO: Diabetes fact sheet (14 November 2024) (2024) · 原始文献
    Type 1 diabetes 'requires daily administration of insulin'; chronic hyperglycaemia leads to serious damage to many body systems.
  • WHO: WHO calls on countries to reduce sugars intake (I-SUG-05) (2015) · 原始文献
    Free sugars <10% of energy (strong), ideally <5%.
  • ADA/EASD: The management of type 1 diabetes in adults: updated 2026 consensus report (2026) · 原始文献
    'Lifelong insulin therapy is essential in type 1 diabetes'; all individuals need glucose and ketone testing supplies; insulin omission or under-dosing is a DKA precipitant.
检索策略

本次审查的文献检索记录（检索式采用原数据库语法）。

数据库日期检索式检索目标命中数纳入数
PubMed2026年10月26日stress hyperglycemia AND (adaptive OR "survival response" OR protective)支持性证据4899
PubMed2026年10月26日Marik PE[au] AND stress hyperglycemia[ti]支持性证据5
PubMed2026年10月26日(hyperglycemia OR "high blood glucose") AND (beneficial OR protective) AND (retina OR brain OR cognition) AND diabetes AND (cohort OR randomized)支持性证据65
Europe PMC2026年10月26日"stress hyperglycemia" AND (adaptive OR protective OR "survival response") AND (TITLE:"hyperglycemia" OR TITLE:"hyperglycaemia")支持性证据245
Europe PMC2026年10月26日("HbA1c" OR "glycated haemoglobin" OR "glycated hemoglobin") AND (TITLE:"validity" OR TITLE:"accuracy" OR TITLE:"limitations") AND (anaemia OR anemia OR hemoglobinopathy) AND review支持性证据44
PubMed2026年10月26日Nathan DM[au] AND "Translating the A1C assay"反对性证据1
PubMed2026年10月26日(HbA1c[ti] OR "glycated hemoglobin"[ti]) AND (complications OR mortality) AND (meta-analysis[pt] OR "cohort"[ti])反对性证据142
PubMed2026年10月26日Lind M[au] AND "Glycemic control and excess mortality in type 1 diabetes"反对性证据6
PubMed2026年10月26日DCCT EDIC AND mortality AND JAMA[ta] AND 2015[dp]反对性证据1
WHO website2026年10月26日Fetched https://www.who.int/news-room/fact-sheets/detail/diabetes指南1

待解决的问题

No outcome data exist on followers who ignored high glucose.

核查深度如何？

13 项相关研究：3 项核查了全文（其中 2 项进行了结构化偏倚风险评估），10 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。

最近一次科学审核: 2026年10月26日

评定结论的变更历史
  1. 2026年10月25日 · 第 1 阶段 · 初始评估: 错误 (高)
  2. 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 错误 (高)
    New studies (ADAG validation of HbA1c, Swedish registry mortality, DCCT/EDIC mortality) strengthen the existing assessment; the only supporting items concern acute stress hyperglycaemia and HbA1c caveats in blood disorders.
    新来源: I-DIAB-106 I-INS-103 I-INS-104 I-DIAB-107 I-DIAB-108 I-INS-137

通俗解释

在应激状态下，血糖可能会短暂升高，这是正常的。但如果血糖在数月乃至数年内一直偏高，就会损害眼睛、肾脏、神经和血管。大型研究表明，长期血糖（糖化血红蛋白，HbA1c）越高，并发症就越多，而降低血糖可以预防失明和肾衰竭。

与该说法相关的研究

支持该说法的研究 (0)

该组中没有研究。

与该说法相矛盾或限制该说法的研究 (10)

  • DCCT: better insulin treatment in type 1 diabetes

    Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    Intensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Does intensive insulin therapy reduce long-term complications in type 1 diabetes?

    研究是如何开展的？

    Multicentre RCT (DCCT)

    研究了多少人、动物或样本？

    1,441; Insulin-dependent (type 1) diabetes

    实际发现了什么？

    Large reductions in all microvascular complications.

    观察到的效应有多大？

    Retinopathy -76%

    研究结果对日常生活意味着什么？

    Insulin protects eyes, kidneys and nerves in type 1 diabetes.

    该研究有哪些局限？

    Open-label; Selected young population

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-07, C-INS-09, C-DIAB-01; shows insulin efficacy and hypoglycaemia cost (C-INS-02 kernel).

    研究结果是否适用于德国和欧洲？

    North American; universally accepted.

    从该研究中明确不能得出什么结论？

    Effects in type 2 diabetes directly.

    科学细节 →

  • How much long-term blood sugar matters (UKPDS 35)

    Stratton IM et al.. BMJ 2000 · PMID 10938048 · DOI 10.1136/bmj.321.7258.405
    队列研究独立交叉核查已核查摘要★ 关键研究

    Each 1% lower HbA1c was linked to 21% fewer diabetes deaths and 37% fewer eye/kidney complications.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Relation of glycaemia over time to complications

    研究是如何开展的？

    Prospective observational analysis within UKPDS (UKPDS 35)

    研究了多少人、动物或样本？

    4,585 (3,642 for RR); UKPDS patients (white, Asian Indian, Afro-Caribbean)

    实际发现了什么？

    Graded risk with HbA1c, no threshold.

    观察到的效应有多大？

    -21% per 1% HbA1c

    研究结果对日常生活意味着什么？

    High sugar damages the body.

    该研究有哪些局限？

    Observational

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-DIAB-01, C-DIAB-02, C-ODD-06 (hyperglycaemia causes complications incl. amputation).

    研究结果是否适用于德国和欧洲？

    UK.

    从该研究中明确不能得出什么结论？

    That pushing HbA1c to normal is always safe.

    科学细节 →

  • UKPDS: tablets or insulin for new type 2 diabetes

    UKPDS Group. Lancet 1998 · PMID 9742976
    随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究

    Better sugar control with tablets or insulin cut eye/kidney complications by a quarter; insulin caused more weight gain and low-sugar episodes.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Intensive control with sulfonylurea or insulin vs diet on complications

    研究是如何开展的？

    Multicentre RCT (UKPDS 33)

    研究了多少人、动物或样本？

    3,867; Newly diagnosed type 2 diabetes, median age 54

    实际发现了什么？

    Microvascular -25%; more hypoglycaemia and weight gain with insulin.

    观察到的效应有多大？

    RR reduction 25% microvascular

    研究结果对日常生活意味着什么？

    Insulin helps prevent complications but has side effects.

    该研究有哪些局限？

    Open-label; Older drug regimens

    它对 Elawady 的具体说法说明了什么？

    Supports weight/hypoglycaemia (C-INS-01); contradicts C-INS-03, C-INS-05, C-DIAB-01.

    研究结果是否适用于德国和欧洲？

    UK; directly relevant.

    从该研究中明确不能得出什么结论？

    That insulin is harmful overall.

    科学细节 →

  • UKPDS legacy: 10 years after the trial

    Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    People treated intensively early with sulfonylureas or insulin had 15% fewer heart attacks and 13% fewer deaths years later.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Do UKPDS benefits persist and do macrovascular effects emerge?

    研究是如何开展的？

    Post-trial monitoring of an RCT (UKPDS 80)

    研究了多少人、动物或样本？

    4,209 randomised; 3,277 monitored; Newly diagnosed type 2 diabetes from UKPDS

    实际发现了什么？

    Legacy reductions in MI and death.

    观察到的效应有多大？

    Death -13% (SU/insulin), -27% (metformin)

    研究结果对日常生活意味着什么？

    Early good control pays off for decades.

    该研究有哪些局限？

    Post-trial therapy not controlled; Questionnaire follow-up

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-03, C-INS-05 and C-DIAB-01: early insulin/SU therapy reduced MI and death long-term.

    研究结果是否适用于德国和欧洲？

    UK; directly relevant.

    从该研究中明确不能得出什么结论？

    Effects of extreme targets in late disease.

    科学细节 →

  • EFSA: how much sugar is safe?

    EFSA NDA Panel et al.. EFSA J 2022 · PMID 35251356 · DOI 10.2903/j.efsa.2022.7074
    风险评估独立交叉核查全文，含结构化偏倚风险评估★ 关键研究

    EFSA found no safe intake level and advises keeping added and free sugars as low as possible.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Can a UL or safe level for dietary sugars be set?

    研究是如何开展的？

    Regulatory scientific opinion with systematic reviews.

    研究了多少人、动物或样本？

    Not applicable; General population

    实际发现了什么？

    Sugars are a well-established hazard for caries; RCTs on surrogate endpoints show causal positive relationship of added/free sugars with obesity and dyslipidaemia (moderate certainty), NAFLD and T2D (low), hypertension (very low); no safe level identified; intake of added and free sugars should be as low as possible in a nutritionally adequate diet.

    观察到的效应有多大？

    Not applicable

    研究结果对日常生活意味着什么？

    Applies to sugar, honey and syrups alike.

    该研究有哪些局限？

    Trials looked at markers (weight, liver fat, blood fats) rather than diseases; cohort studies mostly compared sugar with other calories at equal total energy; few data below 10% of energy.

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-SUG-01, C-SUG-05 (health relevance); supports C-SOD-01.

    研究结果是否适用于德国和欧洲？

    Directly applicable in EU/Germany.

    从该研究中明确不能得出什么结论？

    It cannot name a safe daily amount of sugar; it does not show that sugar is harmful when it does not add extra calories, except for tooth decay.

    科学细节 →

  • Sugary drinks and diabetes risk: pooled cohorts

    Malik VS et al.. Diabetes Care 2010 · PMID 20693348 · DOI 10.2337/dc10-1079
    Meta分析被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究

    People in the highest intake group had a 26% higher risk of type 2 diabetes than those drinking almost none.

    该研究是否支持这一具体说法？ 是 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Is SSB intake associated with incident metabolic syndrome and type 2 diabetes?

    研究是如何开展的？

    Systematic search (MEDLINE to May 2010) and random-effects meta-analysis of prospective cohorts, highest vs lowest SSB quantile.

    研究了多少人、动物或样本？

    11 cohorts; 310,819 participants; 15,043 T2D cases; 19,431 participants/5,803 cases for metabolic syndrome; Adults in prospective cohorts

    实际发现了什么？

    T2D: RR 1.26 (95% CI 1.12-1.41); metabolic syndrome: RR 1.20 (1.02-1.42).

    观察到的效应有多大？

    RR 1.26 (1.12-1.41)

    研究结果对日常生活意味着什么？

    Regular sugary drinks are linked with more diabetes.

    该研究有哪些局限？

    Only MEDLINE; no risk-of-bias assessment; high heterogeneity; observational studies; overlaps with later meta-analyses

    它对 Elawady 的具体说法说明了什么？

    Core evidence for C-SOD-01.

    研究结果是否适用于德国和欧洲？

    High; cohorts from Western populations.

    从该研究中明确不能得出什么结论？

    That sugary drinks alone cause the difference.

    科学细节 →

  • HbA1c reflects average blood sugar

    Nathan DM et al.. Diabetes Care 2008 · PMID 18540046 · DOI 10.2337/dc08-0545
    其他独立交叉核查已核查摘要★ 关键研究

    In 507 people with about 2,700 glucose readings each, HbA1c closely matched the 3-month average blood sugar.

    HbA1c strongly correlates with measured average glucose (R2 0.84).

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Link HbA1c to average glucose.

    研究是如何开展的？

    Observational method study.

    研究了多少人、动物或样本？

    507 people.

    实际发现了什么？

    eAG = 28.7 x A1C - 46.7; R2 0.84.

    观察到的效应有多大？

    HbA1c 7% = about 154 mg/dL.

    研究结果对日常生活意味着什么？

    HbA1c is a reliable average-sugar measure for most people.

    该研究有哪些局限？

    Some individuals deviate.

    它对 Elawady 的具体说法说明了什么？

    Contradicts 'HbA1c is a lie'.

    研究结果是否适用于德国和欧洲？

    Used in Europe.

    从该研究中明确不能得出什么结论？

    Cannot replace glucose checks in anaemia or haemoglobin disorders.

    科学细节 →

  • Blood sugar control and death in type 1 diabetes in Sweden

    Lind M et al.. N Engl J Med 2014 · PMID 25409370 · DOI 10.1056/NEJMoa1408214
    队列研究独立交叉核查已核查摘要★ 关键研究

    People with type 1 diabetes died about 3.5 times as often as matched controls; with very high HbA1c the risk was about 8.5 times higher.

    Mortality rises steeply with HbA1c (HR 8.51 at >=9.7%).

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Measure excess mortality in T1D by glucose control.

    研究是如何开展的？

    Nationwide register with matched controls.

    研究了多少人、动物或样本？

    33,915 patients, 169,249 controls.

    实际发现了什么？

    Higher HbA1c, higher death risk; excess risk even with good control.

    观察到的效应有多大？

    HR 3.52 overall; 8.51 at HbA1c >=9.7%.

    研究结果对日常生活意味着什么？

    Type 1 diabetes shortens life, especially with high sugar.

    该研究有哪些局限？

    Observational data.

    它对 Elawady 的具体说法说明了什么？

    Contradicts denial of T1D complications and 'high sugar protects'.

    研究结果是否适用于德国和欧洲？

    Swedish data, directly applicable to Europe.

    从该研究中明确不能得出什么结论？

    Cannot prove that lowering HbA1c alone removes all excess risk.

    科学细节 →

  • Long-term survival after intensive insulin treatment in type 1 diabetes

    Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107
    随机对照试验独立交叉核查已核查摘要★ 关键研究

    People who received intensive insulin treatment for about 6.5 years had about one third lower death risk 27 years later.

    Higher HbA1c associated with mortality (HR 1.56 per 10% relative increase).

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Test whether intensive insulin therapy affects long-term survival.

    研究是如何开展的？

    Follow-up of a randomised trial.

    研究了多少人、动物或样本？

    1,441 young adults with T1D.

    实际发现了什么？

    43 vs 64 deaths; HR 0.67.

    观察到的效应有多大？

    -109 deaths per 100,000 patient-years.

    研究结果对日常生活意味着什么？

    Good insulin treatment helps people with type 1 diabetes live longer.

    该研究有哪些局限？

    Few deaths; later years observational.

    它对 Elawady 的具体说法说明了什么？

    Contradicts 'insulin does not treat diabetes'.

    研究结果是否适用于德国和欧洲？

    Applicable to Europe.

    从该研究中明确不能得出什么结论？

    Cannot separate effects of later care.

    科学细节 →

  • WHO: key facts on diabetes

    World Health Organization. WHO fact sheet 2024
    指南 / 立场声明独立交叉核查已核查全文★ 关键研究

    Type 1 diabetes requires daily insulin; long-term high blood sugar damages nerves, blood vessels and organs.

    Chronic hyperglycaemia causes serious organ damage.

    该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Inform the public.

    研究是如何开展的？

    Fact sheet.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    T1D needs daily insulin.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    Type 1 diabetes needs insulin every day.

    该研究有哪些局限？

    Not graded.

    它对 Elawady 的具体说法说明了什么？

    Contradicts C-INS-07 and C-DIAB-01.

    研究结果是否适用于德国和欧洲？

    Global.

    从该研究中明确不能得出什么结论？

    Not applicable.

    科学细节 →

结果不一或不明确的研究 (3)

  • Very tight blood sugar control in intensive care

    NICE-SUGAR Study Investigators; Finfer S et al.. N Engl J Med 2009 · PMID 19318384 · DOI 10.1056/NEJMoa0810625
    随机对照试验被 Tayebat 档案网站引用已核查摘要

    Aiming for normal blood sugar in ICU patients raised deaths from 24.9% to 27.5%.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Optimal blood glucose target in critically ill ICU patients

    研究是如何开展的？

    International multicentre RCT

    研究了多少人、动物或样本？

    6,104; Adult ICU patients expected to stay >=3 days

    实际发现了什么？

    Higher 90-day mortality and 13-fold more severe hypoglycaemia with intensive control.

    观察到的效应有多大？

    OR 1.14 (1.02-1.28)

    研究结果对日常生活意味着什么？

    In very sick hospital patients, moderate sugar targets are safer.

    该研究有哪些局限？

    ICU population, not ambulatory diabetes; Open-label

    它对 Elawady 的具体说法说明了什么？

    Supports that overly tight targets harm (C-INS-04); both arms received insulin, so it does not support insulin avoidance.

    研究结果是否适用于德国和欧洲？

    Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

    从该研究中明确不能得出什么结论？

    Anything about insulin therapy in people with diabetes at home.

    科学细节 →

  • Is high blood sugar during severe illness protective?

    Marik PE, Bellomo R. Crit Care 2013 · PMID 23470218 · DOI 10.1186/cc12514
    叙述性综述独立交叉核查已核查摘要★ 关键研究

    Critical-care experts argue that a short-term rise in sugar during severe illness may be a survival response; this does not apply to long-term diabetes.

    Acute stress hyperglycaemia may be adaptive; does not apply to chronic diabetes.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Argue that acute stress hyperglycaemia is adaptive.

    研究是如何开展的？

    Narrative review.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    Tight ICU glucose control did not help; stress hyperglycaemia may be protective short term.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    Brief high sugar in acute illness is not the same as diabetes.

    该研究有哪些局限？

    Opinion piece.

    它对 Elawady 的具体说法说明了什么？

    Supports only the acute kernel of C-DIAB-01.

    研究结果是否适用于德国和欧洲？

    Applicable.

    从该研究中明确不能得出什么结论？

    Cannot justify ignoring chronic high glucose.

    科学细节 →

  • When HbA1c can be misleading

    Samajdar SS et al.. Lancet Reg Health Southeast Asia 2026 · PMID 41743216 · DOI 10.1016/j.lansea.2026.100724
    叙述性综述独立交叉核查已核查摘要★ 关键研究

    Anaemia, inherited haemoglobin disorders and G6PD deficiency can distort HbA1c, so it should be combined with direct glucose measurements.

    HbA1c has known limitations in anaemia/haemoglobinopathies; does not make it 'a lie'.

    该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估

    原始文献 · 科学细节

    研究通俗解读
    研究人员想了解什么？

    Review HbA1c pitfalls in India.

    研究是如何开展的？

    Narrative review.

    研究了多少人、动物或样本？

    Not applicable.

    实际发现了什么？

    HbA1c unreliable in some conditions.

    观察到的效应有多大？

    Not applicable.

    研究结果对日常生活意味着什么？

    HbA1c is useful but must be interpreted with care.

    该研究有哪些局限？

    Narrative.

    它对 Elawady 的具体说法说明了什么？

    Partly supports scepticism about HbA1c in specific conditions.

    研究结果是否适用于德国和欧洲？

    Same caveats in Europe/Egypt.

    从该研究中明确不能得出什么结论？

    Cannot support abandoning HbA1c or glucose testing.

    科学细节 →

地区背景

德国 / 欧盟

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

埃及

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

在我的国家适用什么？

一般科学评估

错误 长期高血糖是有害的；否认糖尿病的存在是错误且危险的。

该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。

参考文献

  1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
  2. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.. Stratton IM et al.. BMJ 2000 · PMID 10938048 · DOI 10.1136/bmj.321.7258.405
  3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742976
  4. 10-year follow-up of intensive glucose control in type 2 diabetes.. Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
  5. Tolerable upper intake level for dietary sugars.. EFSA NDA Panel et al.. EFSA J 2022 · PMID 35251356 · DOI 10.2903/j.efsa.2022.7074
  6. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis.. Malik VS et al.. Diabetes Care 2010 · PMID 20693348 · DOI 10.2337/dc10-1079
  7. Translating the A1C assay into estimated average glucose values.. Nathan DM et al.. Diabetes Care 2008 · PMID 18540046 · DOI 10.2337/dc08-0545
  8. Glycemic control and excess mortality in type 1 diabetes.. Lind M et al.. N Engl J Med 2014 · PMID 25409370 · DOI 10.1056/NEJMoa1408214
  9. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.. Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107
  10. Diabetes (fact sheet). World Health Organization. WHO fact sheet 2024
  11. Intensive versus conventional glucose control in critically ill patients.. NICE-SUGAR Study Investigators; Finfer S et al.. N Engl J Med 2009 · PMID 19318384 · DOI 10.1056/NEJMoa0810625
  12. Stress hyperglycemia: an essential survival response!. Marik PE, Bellomo R. Crit Care 2013 · PMID 23470218 · DOI 10.1186/cc12514
  13. The limitations and fallacies of relying on glycosylated hemoglobin for diagnosing and monitoring diabetes in Indian populations.. Samajdar SS et al.. Lancet Reg Health Southeast Asia 2026 · PMID 41743216 · DOI 10.1016/j.lansea.2026.100724

← 返回概览